Broomfield, Colorado (PRWEB) June 01, 2021 Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company
Predictive Health Diagnostics Company s Proprietary Computational Technology Enables Development of Specialty Diagnostic Tests to Improve Patient Care
Company announces its business strategy including test development, commercialization, intellectual property, and reimbursement initiatives
Data-driven technology platform innovates specialty diagnostic tests for diseases with the largest unmet medical needs
News provided by
Share this article
IRVINE, Calif., June 1, 2021 /PRNewswire/
Predictive Health Diagnostics Company, Inc. ( PHDC or the Company ), a diagnostics development platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced its business strategy and development plan, including upcoming corporate milestones.
On May 25, 2021, the Office for Civil Rights (OCR) within the U.S. Department of Health and Human Services (HHS), announced that Peachstate Health Management, LLC d/b/a AEON Clinical.
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
News provided by
Share this article
Share this article
AUSTIN, Texas, May 28, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal s™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. Guardant s MRD test performance claims are incomplete or unsupported by clinical evidence, and can be misinterpreted by physicians and patients.
calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which
gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2
RARITAN, N.J., May 21, 2021 /CNW/ Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world s largest pure-play in vitro diagnostics companies, today announced the launch of the first quantitative COVID-19 IgG antibody test in addition to a total COVID-19 nucleocapsid antibody test.
Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test. Both tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 and are processed on Ortho s trusted VITROS